Email a Friend
Print ArticleProstate Enlargement/BPH Health Center
Do Prostate Drugs Harm Bones?
Oct. 7, 2008 -- Millions of men suffer from an enlarged prostate gland. There are many drugs available for treatment, but what effects do these drugs have on bone health?
Researchers estimate that more than 8 million men in the U.S. ages 50-79 will have to deal with an enlarged prostate by the year 2010.
Drugs that treat enlarged prostate, or benign prostatic hyperplasia (BPH), come in two groups: 5-alpha reductase inhibitors and alpha-blockers.
Researchers led by Steven J. Jacobsen, MD, of Kaiser Permanente Southern California, wanted to find out if there is any connection between 5-alpha reductase inhibitors and hip fractures. Examples of these drugs include Proscar and Avodart.
These drugs treat BPH in part by blocking testosterone from converting to dihydrotestosterone. The researchers write that other studies "suggest that dihydrotestosterone might have a role in bone metabolism, but no clear evidence exists to support this theory."
The researchers gathered data on 7,076 men (45 years and older) from 1997 to 2006, all who had hip fractures. They compared them with a group of 7,076 similar men who did not have a hip fracture.
A similar percentage of men in each group had benign prostatic hyperplasia.
The researchers found:
- 109 of the men with hip fractures had taken a 5-alpha reductase inhibitor
- 141 of the men without hip fractures had taken a 5-alpha reductase inhibitor
Their conclusion: 5-alpha reductase inhibitors are not linked to an increased risk of hip fracture; instead, they may decrease risk of hip fracture.
Interestingly, the researchers also found a modest increase in hip fracture risk in the men who took alpha-blockers. There was more use of alpha-blockers (32%) in men with hip fractures vs. men without hip fractures (30%). Since this was not a primary focus of the study, the researchers write that this finding warrants further investigation.
Alpha-blockers include Flomax, Uroxatral, Cardura, and Hytrin.
WebMD phoned the trade organization PhMRA for reaction, but they said their policy is not to comment on these types of studies regarding classes of drugs or individual drugmakers.
The researchers note that they only studied older men and that more research should be done on the long-term risks of these drugs in younger men.
The study appears in the Oct. 8 issue of The Journal of the American Medical Association.
del.icio.us
Indication
Uroxatral® (alfuzosin HCl 10 mg extended-release tablets) is an alpha1-blocker for the treatment of the signs and symptoms of BPH.
Important Safety Information
Do not take UROXATRAL if you have liver problems or if you are taking antifungal drugs like ketoconazole or itraconazole, or HIV drugs like ritonavir.
UROXATRAL can cause a sudden drop in blood pressure, especially when starting treatment. This may lead to fainting, dizziness, and lightheadedness. Do not drive, operate machinery, or do any dangerous activity until you know how UROXATRAL will affect you. This is especially important if you already have a problem with low blood pressure or take medicines to treat high blood pressure. There may be an increased risk of low blood pressure and fainting when taking UROXATRAL in combination with blood pressure medication or nitrates, or erectile dysfunction medication.
If considering cataract surgery (clouding of the eyes), tell your eye surgeon that you are currently taking UROXATRAL or have previously been treated with an alpha-blocker.
Before taking UROXATRAL, tell your doctor if you have kidney problems.
Also, tell your doctor if you or any family member(s) have or take medications for a rare heart condition known as congenital prolongation of the QT interval.
BPH and prostate cancer can cause the same symptoms. However, UROXATRAL is not a treatment for prostate cancer.
The most common side effects with UROXATRAL are dizziness, upper respiratory tract infection, headache, and tiredness.
Please see UROXATRAL full prescribing information.
